SMi Group Reports: Following the FDA’s release of a Biosimilar Action Plan, this year’s Biosimilars USA conference promises to explore the developments in biosimilar drug development During a ...

Japanese drug firm Chugai Pharmaceutical has established competitive advantages due to its alliance with majority shareholder Roche as well as its internal research and development engine. While ...

The FDA granted orphan drug designation to HLX22 for gastric cancer, advancing global phase 3 trials to improve first-line ...

biosimilars, as well as private label and other over-the-counter (OTC) medications. Swaminathan: Coya Therapeutics, founded in 2020, is a clinical-stage biotechnology company headquartered in ...

Since September, Dr Savoy has been active as an independent consultant, advising clients in biosimilar and biobetter drug developments ... at Roche involved the design and implementation of ...

Employees at banking giant JPMorgan Chase claimed in a new class action suit that the company mismanaged their benefits, ...

South Korea’s leading biosimilar drug developer Celltrion Inc. said on Monday it is set to sell Steqeyma, a biosimilar to ...

Adds Regeneron comment Regeneron Pharmaceuticals (NASDAQ:REGN) dropped 1.6% after the company's loss against Amgen (NASDAQ:AMGN) in a patent case over Regeneron's blockbuster Eylea drug was affirmed ...

Pharmacokinetics studies how a drug is absorbed into the body over time — how it gets distributed through the blood and to ...

The U.S. Food and Drug Administration (FDA) has released a series of announcements covering a wide range of initiatives and ...